BTIG Maintains Buy on Spyre Therapeutics, Lowers Price Target to $121

Benzinga · 3d ago
BTIG analyst Julian Harrison maintains Spyre Therapeutics (NASDAQ:SYRE) with a Buy and lowers the price target from $132 to $121.